



## **Analgesic Properties of Aqueous Leaf Extract of *Alchornea cordifolia* (Christmas Bush) on Wistar Rats**

**E. Harrison Ogheneochuko<sup>a</sup>, Dikoye Peters<sup>a</sup>, C. Awarajih Uwaezuoke<sup>a</sup> and Ukoro Blessing<sup>b\*</sup>**

<sup>a</sup> Department of Biochemistry, Faculty of Sciences University of Port Harcourt, Port Harcourt, Choba, Rivers State, Nigeria.

<sup>b</sup> Department of Human Physiology, College of Health Sciences University of Port Harcourt, Port Harcourt, Choba, Rivers State, Nigeria.

### **Authors' contributions**

*This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.*

### **Article Information**

DOI: 10.9734/AJBGMB/2022/v10i230239

### **Open Peer Review History:**

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/82721>

**Original Research Article**

**Received 07 November 2021  
Accepted 14 January 2022  
Published 21 January 2022**

### **ABSTRACT**

Disease conditions leading to pain are major healthcare problem worldwide. Incidences of pain related disorders have been on the increase worldwide. Although, several synthetic agents are available in treatment of these disorders, long-term usage has been reported to potentially lead to undesired effect. Hence Analgesic effects of aqueous leaf extract of *Alchornea cordifolia* on wistar rats were investigated. Twenty wistar rats of both genders weighing between 110-178 g were utilized. Acetic acid was used for induction of pain. The rats were grouped into five groups of 4 per group in each study. Groups 3, 4 and 5 received 400, 800 mg/kg b.w of aqueous extract and reference drug respectively after induction. Groups 1 and 2 served as normal and negative controls. Rats were sacrificed and blood samples collected for hematological and biochemical analyses. Phytochemical screening of the plant revealed the presence of alkaloid, phenolic compounds, Tannins and Quinine. The result showed significant increase ( $p \leq 0.05$ ) in paw size, and number of writhing in group 2 and non-significant reduction ( $p \geq 0.05$ ) in group 4 were seen when contrasted to group 1 and 2 respectively. Highest pain inhibition (16%) was seen in group 4. Significant ( $p \leq 0.05$ ) increase in C-reactive protein and nitric oxide concentrations were observed in groups 3 and 4 when

\*Corresponding author: E-mail: [blessing\\_ukoro@uniport.edu.ng](mailto:blessing_ukoro@uniport.edu.ng);

contrasted to group 2 in the study. Non-significant differences in all hematological parameters in all treated groups were observed when compared to group 2. Aqueous leaf extract of *Alchornea cordifolia* displayed an analgesic effect.

**Keywords:** Analgesic; *Alchornea cordifolia*; pains; medicinal plants.

## 1. INTRODUCTION

Disease conditions leading to pain are major healthcare problem worldwide. Incidences of pain-related issues have been on the increase worldwide. Although, several synthetic agents are available in treatment of these disorders, long-term usage has been reported by Qandil to potentially lead to the undesired effect. Plants have a reputation as remedies in ethnomedicine for the management of pain [1]. Extracts from plant reportedly possess vast secondary metabolites with myriad biological activities [2]. Plants are an interesting focal point for novel analgesic compounds. This necessitates the need for this study which was designed to evaluate the analgesic properties of aqueous leaf extract of *Alchornea cordifolia* on wistar rats. Synthetic analgesics drugs usage have been gaining popularity in the last few decades due to the physical, mental and exhaustive nature of work and occupation of many people especially in impoverished countries. Studies have established that prolonged usage of over the counter and prescription analgesic medication are linked to side effects which ranges from mild (such as irritation and nausea) to severe (such as Renal Failure, Respiratory Distress, Hepatotoxicity, Gastric and Duodenal ulcers, addiction amongst others) adverse effect [3]. Some of these effects may be temporal or permanent. Therefore, finding un-toxic and efficient drug to lower or manage pain remains a burden. Few years past, phytochemicals were the main source for evaluating analgesic properties of plants, some (phytoconstituents) of which are currently looked at as components (bioactive) for analgesic, actions [4].

There are different disease conditions which are associated with acute or chronic pains, such conditions has been reported by several researchers [5-116].

*Alchornea cordifolia* commonly known as Christmas bush is a vertical shrub or a perennial small tree with a lightly granulated bark, greyish and woody stem and a simple, alternate heart shaped based leaves [117]. Reported as an

evergreen small tree from the *Euphobiaceae* family, Boniface et al. [118] opined that the plant parts are ethnobotanically used in management of myriad ailments.

Its medicinal properties have been reported by Boniface et al. [118] to include anti-diabetic, spasmolytic, anti-bacterial and anti-microbial. Over the years, more revelations on the medicinal potentials of *Alchornea cordifolia* including the Anti-*Helicobacter Pylori* induced-gastric ulcers [119]. Report by Agrawal et al. (2003) suggest that *Alchornea cordifolia* leaf alongside leaves from *Boerhavia Diffusa* plants possess Antifungal property although the level of this property is yet to be fully understood. The leaves, bark and roots have been reportedly used in ethnomedicine by the Urhobo people of Nigeria in curing conjunctivitis, amoebic dysenteries and venereal diseases [118]. Hence, given the myriad spectrum of ethnobotanical applications and reported multiple pharmacological properties attributed to *Alchornea cordifolia* as a medicinally important plant, this research was designed to further investigate the biological activities of this specie by evaluating analgesic properties of aqueous leaf extract on wistar rats.

## 2. MATERIALS AND METHODS

### 2.1 Study Design

The Wistar rats were purchased from the Department of Pharmacy, Faculty of Pharmaceutical Science, University of Port Harcourt, Rivers state, Nigeria. They were housed in different cages by groups with renewable bedding, and were fed with standard rat feed and clean water, allowing them to acclimatize for fourteen days under normal temperature, humidity and light-dark cycle. After acclimatization, the animals were weighed and divided into 5 groups for analgesic study.

Acetic acid induces an inflammatory response in the abdominal cavity, with subsequent activation of nociceptors [120]. When animals are intraperitoneally injected with acetic acid, a painful reaction and acute inflammation emerge in the peritoneal area.

**Table 1. Experimental design for analgesic study**

Groups	Description	Dose
Group 1	Normal control	No induction
Group 2	Negative control	1% acetic acid
Group 3	<i>Alchornea cordifolia</i> aqueous extract	1% acetic acid + 400mg/kg
Group 4	<i>Alchornea cordifolia</i> aqueous extract	1% acetic acid + 800mg/kg
Group 5	Reference drug	1% acetic acid + 50mg Aspirin

## 2.2 Plant Collection and Identification

The fresh leaf of *Alchornea Cordifolia* was obtained from Ekrejeta in Abraka in Ethiop East Local Government area of Delta State, Nigeria. After collection, the plant was sent to the Department of Plant Science and Biotechnology, University of Port Harcourt, where it was identified with. The plant was sent to the university of Portharcourt herbarium where it was identify by Dr. Ekeke chimezie and deposit at the herbarium with herbarium number UPH/V/1436.



**Fig. 1. Young *Alchornea cordifolia* plant in its natural habit**

Source: (Researcher)

## 2.3 Extract Preparation

The leaves were properly washed in running tap H<sub>2</sub>O and allowed to air dry, and blend into powder form. 25g of the powdered was macerated in 100 ml of deionized water for 24 hours under mechanical agitation at room temperature. The suspension was filtered using whatman filter paper and dried in a water-bath at approximately 55°C. Crude extract gotten was store at 4°C.

## 2.4 Qualitative Phytochemical Screening of *Alchornea cordifolia*

The extract of *Alchornea cordifolia* was qualitatively screened to find out the presence of

secondary metabolites and then relate its activity. This shows the presence or absence of these metabolites.

### Alkaloids

Mayer's reagent was used, plant extract of *Alchornea cordifolia* (0.5 g) was added to 5 ml of dilute sulphoric acid (1%) on a steam bath, and then filtered. The filtrate was transferred into a test tube and a few drops of Mayer's reagents were added, white creamy participate will appear which indicatesalkaloids is present [121].

### Saponins

Froth test was employed; 50 mg plant extract diluted with distilled water up to 20 ml. The mixture was vigorously shaken for 15 minutes; two cm layer of foam will indicate the presence of saponins contents in a graduated cylinder [122].

### Test for Flavonoids

Alkaline reagent method was employed. Aqueous solution of plant extract was treated with ammonium hydroxide 10% solution. Yellow fluorescence will appear and later the yellow colouration will becolourless when there is addition of a few drop of dilute acid this indicates the presence of flavonoids content.

### Tannins

Ferric chloride (FeCl<sub>3</sub>) test was used, 0.5 grams of the extract was dissolved in 50 ml of distilled water and sieved through a muslin filter. Then, a small amount of filtrate was transferred to a test tube and a few drops of 5% ferric chloride solution were addedto form blue-black precipitation. This indicates the presence of tannins [123].

### Terpenoids

Salkowski's test was employed; little quantity of extract was mixed with 2 ml of chloroform and sieved through a filter paper. Three drops of concentrated H<sub>2</sub>S<sub>0</sub>4were cautiously added into

the filtrate. The presence of terpenes was indicated by a reddish brown coloration of the inter face was formed to show positive results for the presence of terpenoids [124].

## 2.5 Haematological Analysis

### Total WBC count

**Method:** Improved Neubauer ruled chamber

**Principle:** Whole blood is diluted 1 in 20 in an acid reagent which haemolyzes the red cells leaving the white cells to be counted.

### Reagents

- i. Turk's solution.

**Procedure:** White blood cell count was done manually with the use of counting chambers. 0.38 ml of Turk's solution was aliquoted into a plain bottle, 20 ul of whole blood collected with an EDTA bottle, was pipetted to each bottles, it was mixed gently for sedimenting. The counting chamber was covered with a cover slide and the edges sealed of distilled water. The solution in the plain bottle was then charged into the counting chamber at an angle of 45°, it was mounted on the microscope and focused using X40 magnification, the cells were accurately counted and the value was then multiplied by 50 and divided by 1000 to get the actual white blood cell count. This was done for all the samples.

### White blood cell differential count

**Method:** Leishman stain [125]

**Principle:** Methanolic mixture-based of Methylene blue and eosin. The methanolic stock solution is undisturbed serving the intention of directly fixing the smear thereby eliminating a prefixing step.

### Reagents:

- i. Leishman's stain

**Procedure:** A thin film was made on a microscope slide for each sample it was allowed to air dry. It was stained with Leishman's stain for 2-3 minutes, after which, it was diluted with distilled water for another 2 minutes then allowed to air dry. A drop of oil immersion introduced and mounted on the microscope using X100 magnification to count the different differential cells (neutrophils, lymphocytes, monocytes, eosinophils and basophils). The cells were noted and documented. This was replicated for all collected samples

## 2.6 Data Analysis

Laboratory data were analyzed with statistical packages for Social sciences (SPSS version 20). Values were reported as mean plus-minus standard error of mean employing analysis of variance (ANOVA) and least significant difference (LSD) for multiple comparison.

## 3. RESULT AND DISCUSSION

**Table 2. Phytochemical Analysis of *Alcharnia carclifolia***

Alkaloid	positive
Phenolic_compound	positive
Tannins	positive
Flavonoid	negative
Saponnin	positive
Quinine	Positive
Coumarin	negative
Protein	negative
Cardiac glycoside	negative
Steroid	negative

**Table 3. Effect of oral administration of aqueous leave extract of *Alchornea cordifolia* on acetic acid induced writhing in wistar rats**

Group	Treatment	Average number of Writhing	Percentage Inhibition (%)
1	Control (0.5 ml distilled water)	0.00±0.00 <sup>a</sup>	-
2	Control (-ve) 1% acetic acid	4.50±1.55 <sup>a</sup>	-
3	1% acetic acid + 400 mg/kg <i>Alchornea cordifolia</i>	4.25±0.48	5.56
4	1% acetic acid + 800 mg/kg <i>Alchornea cordifolia</i>	3.75±0.48	16.67
5	1% acetic acid + 300 mg/kg Aspirin	4.25±0.48	5.56

Values are reported as mean ± standard error of mean (M±SEM) (n=4). Values with similar superscript letters indicate statistical significant differences (p≤ 0.05) down the column while those without superscripts show non-significant differences (p≥ 0.05) down the column when compared with the control and between groups.

**Table 4. Effect of aqueous leave extract of *Alchornea cordifolia* on interleukin-6, C-reactive protein and nitric oxide concentration of acetic acid induced-writhing in wistar rats**

Group	Treatment	Interleukin-6 (pg/ml)	C-reactive protein (mg/l)	Nitric Oxide (mg/ml)
1	Control (0.5ml distilled water)	249.75±59.79	0.06±0.00	0.09±0.00
2	Control (-ve) 1% acetic acid	180.05±8.80 <sup>a</sup>	0.50±0.25	0.57±0.27
3	1% acetic acid + 400mg/kg <i>Alchornea cordifolia</i>	109.03±20.74	0.42±0.13	0.11±0.04 <sup>a,b</sup>
4	1% acetic acid + 800mg/kg <i>Alchornea cordifolia</i>	80.48±17.80 <sup>a</sup>	0.74±0.43	0.77±0.31 <sup>a</sup>
5	1% acetic acid + 300mg Aspirin	119.90±0.00	0.05±0.00	0.84±0.00 <sup>b</sup>

Values are reported as mean ± standard error of mean (M±SEM) (n =4). Values with similar superscript letters indicate statistical significant differences (p≤ 0.05) down the column while those without superscripts show non-significant differences (p≥ 0.05) down the column when compared with the control and between groups.

**Table 5. Effect of aqueous leave extract of *Alchornea cordifolia* on some haematological parameters of acetic acid induced-writhing in wistar rats**

Group	Treatment	ESR (mm/hour)	WBC (X 10 <sup>9</sup> /L)	Neutrophils (%)	Lymphocytes (%)	Monocytes (%)	Eosinophils (%)	Basophils (%)
1	Control (0.5ml distilled water)	0.00±0.00	9.00±0.24	40.00±1.22	48.50±0.61	5.00±0.41 <sup>a</sup>	1.50±0.20 <sup>a</sup>	0.00±0.00
2	Control (-ve) 1% acetic acid	11.50±1.43 <sup>a</sup>	13.15±0.27	39.00±0.41	40.00±2.04 <sup>a</sup>	16.50±3.06 <sup>a</sup>	4.50±0.61 <sup>a</sup>	0.00±0.00 <sup>a</sup>
3	1% acetic acid + 400mg/kg <i>Alchornea cordifolia</i>	30.00±11.02 <sup>a,b</sup>	21.60±7.60	32.75±2.17 <sup>a</sup>	51.50±3.40 <sup>a,b</sup>	12.25±2.56	2.50±0.65	0.75±0.25 <sup>b</sup>
4	1% acetic acid + 800mg/kg <i>Alchornea cordifolia</i>	28.00±7.48 <sup>b</sup>	12.70±2.78	40.25±4.48	43.75±3.94	10.00±1.41 <sup>a</sup>	4.75±1.18	1.75±0.63 <sup>a,b,c</sup>
5	1% acetic acid + Aspirin	9.33±1.89 <sup>b</sup>	11.80±1.53	46.00±2.27 <sup>a</sup>	42.00±3.56 <sup>b</sup>	7.67±1.18 <sup>a</sup>	3.67±1.03	0.50±0.29 <sup>c</sup>

Values are reported as mean ± standard error of mean (M±SEM) (n =4). Values with similar superscript letters indicate statistical significant differences (p≤ 0.05) down the column while those without superscripts show non-significant differences (p≥ 0.05) down the column when compared with the control and between groups

Table 3 showed a non-significant decrease ( $p \geq 0.05$ ) in the number of writhing in group 3, 4 and 5 when compared with group 2.

Table 3 also revealed a non-significant decrease ( $p \geq 0.05$ ) in the number of writhing in group 4 when compared with group 3, a non-significant decrease ( $p \geq 0.05$ ) in the number of writhing in group 4 when compared with group 5.

Table 3 further revealed greater percentage inhibition in group 4 when compared with groups 3 and 5.

Table 4 showed a significant decrease ( $p \leq 0.05$ ) in interleukin concentration in group 4, a non-significant decrease ( $p \geq 0.05$ ) in group 3 and group 5 when compared with group 2. Also, a non-significant increase ( $p \geq 0.05$ ) in interleukin concentration in group 3 when compared with group 4, a non-significant decrease ( $p \geq 0.05$ ) in interleukin concentration in groups 3 and 4 when compared with group 5.

Table 4 also showed a non-significant decrease in C-reactive protein levels in group 3 and 5, non-significant increase ( $p \geq 0.05$ ) in the C-reactive protein levels in group 4 when compared with group 2. Also, a non-significant increase ( $p \geq 0.05$ ) in the C-reactive protein levels in groups 3 and 4 when compared with group 5.

Table 4 further revealed a non-significant decrease ( $p \geq 0.05$ ) in nitric oxide levels in group 3, non-significant increase ( $p \geq 0.05$ ) in nitric oxide levels in group 4 and 5 when compared with group 2. The Table also showed a significant decrease ( $p \leq 0.05$ ) in nitric oxide levels in group 3 when compared with group 4, a significant decrease ( $p \leq 0.05$ ) in the nitric acid levels in group 3 when compared with group 5.

#### 4. DISCUSSION OF FINDINGS

Writhings generated by parenteral administration of acetic acid in rodents is due to profound pain of endogenous nature which recurs over a time period [126]. Investigation on the analgesic properties of *Alchornea cordifolia* (Tables 3- 4) showed a non-significant decrease ( $p \geq 0.05$ ) in the number writhing in the 400 and 800mg/kg *Alchornea cordifolia* treated groups, implying ability of *Alchornea cordifolia* to have potential analgesic properties. This finding agrees with [127] who reported a significant analgesic effect with 400 and 800mg/kg of *Alchornea cordifolia*

leaves extract. The analgesic effects of *Alchornea cordifolia* could be attributed to alkaloids and terpenes reportedly found in leaf.

Aspirin is an analgesic used in management of pain. The study found that *Alchornea cordifolia* extract at 800mg/kg treated group showed non-significant reduction ( $p \geq 0.05$ ) in writhing display compared with aspirin treated group, implying extract ability to block signals transmitted to brain and spinal cord in reaction to pain due to irritation, which causes release of mediators such as prostaglandins [126] thereby elevating to nociceptors sensitivity.

Furthermore, the analgesic investigations (Table 5) shows greater percentage inhibition at 800mg/kg against 400 mg/kg *Alchornea cordifolia* and aspirin treated groups, which is an indication of dose-dependent analgesic effect in conformity with [127] findings.

The study also observed decreased in interleukin-6, C-reactive protein and NO in the acetic acid-induced animals after dosing with *Alchornea cordifolia* aqueous leaf extract at 400 and 800 mg/kg b.w. The ESR, WBC, lymphocytes levels were significantly increased ( $p \leq 0.05$ ). However, neutrophils monocytes and eosinophils levels revealed non-significant decrease ( $p \geq 0.05$ ).

#### 5. CONCLUSION

This research findings indicates that *Alchornea cordifolia* at 400 and 800 mg/kg showed potential analgesic properties.

#### ETHICAL APPROVAL

An approval for this study was obtained from the Centre for Research Ethics and Management of the University of Port Harcourt with approval.

#### COMPETING INTERESTS

Authors have declared that no competing interests exist.

#### REFERENCES

1. Sofidiya MO, Imeh E, Ezeani C, Aigbe F.R. & Akindele AJ. Antinociceptive and anti-inflammatory activities of ethanolic extract of *Alafia barteri*. Brazilian Journal of

- Pharmaceutical Sciences, (2014).24, 348–354
2. Chung HJ, Lee HS, Shin JS, Lee SH, Park, BM, Youn YS, Lee SK. Modulation of acute and chronic inflammatory processes by a traditional medicine preparation GCSB-5 both in vitro and in vivo animal models. *Journal of Ethnopharmacology*. 2010;130:450–459.
  3. Marret E, Kurdi O, Zufferey P, Bonnet F. Effect of non-steroidal anti-inflammatory drugs on patient-controlled analgesia morphine side effects: Meta- analysis of randomized controlled trials. *Journal of Anesthesiology*. 2005;102:1249-1260.
  4. Kalpesh RP, Umesh BM, Banappa SU, Sameer NG, Sateesh B, Sanjay JS, Shreesh O, Chandragouda RP. Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals. *International Journal of Molecular Science*. 2019;20:4367-4404.
  5. Actor J. Elsevier's Integrated Review Immunology and Microbiology (Second edition.); 2012. DOI:10.1016/B978-0-323-07447-6.00002-8
  6. Akpa P, Emem-chioma C, Odia OJ. Current epidemiology of hypertension in Port Harcourt metropolis, Rivers state, Nigeria. *Port Harcourt Medical Journal*. 2008;2:218- 223.
  7. Alberts B, Johnson A, Lewis M, Raff M, Roberts K, Walter P. Leukocyte also known as macrophages functions and percentage breakdown. *Molecular Biology of the Cell* (4th ed.). New York: Garland Science. American Diabetes Association. AD Standards of medical care in diabetes - 2013. *Diabetes Care*. 2002;36(Suppl.1): S11-S66.
  8. Artunc Ulkumen, Pala HG, Calik E, Oruc Koltan S. platelet distribution width(PDW):a putative marker for threatned preterm labour. *Pakistan Journal of Medical Sciences*. 2014;30(4):745-748
  9. Dinc B, Oskay A, Dinc SE, Bas B, Tekin S. New parameter in diagnosis of acute appendicitis: Platelet distribution width, *World Journal of Gastroenterology*. 2003; 21(6):182-1826.
  10. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. *Journal of Human Hypertension*. 2015;17:223–230.
  11. Karagoz D, Alacacioglu A, Bilgi O, et al. Patelet count and Platelet distribution width increase in lung cancer patients. *Anotolian Journal of Clinical Investigation*. 2009;3:32-34.
  12. Barer MR. The natural history of infection. *Medical Microbiology*. Elsevier. 2012; 168173. DOI:10.1016/b978-0-7020-4089-4.00029-9. ISBN 978-0-7020-4089-4
  13. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. *Journal of Human Hypertension*. 2005;19:149–154.
  14. Cheung BM. The hypertension-diabetes continuum. *J Cardiovasc Pharmacol*. 2010;55:333–9. This is a brief review of the overlap between hypertension and type 2 diabetes that proposes there is a spectrum ranging from hypertension without dysglycemia to type 2 diabetes without elevated blood pressure.
  15. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. *Blood*. 2004;103:2096-104.
  16. Chao WC, Yen CL, Wu YH, Chen SY, Hsieh CY, Chang TC, Ou HY, Shieh CC. Increased resisten may suppress ractive oxygen species production and inflammasome activationin type 2 diabetic patients with pulmonary tuberculosis infection. *Microbes Infection*. 2015;17(3): 195-204. DOI: 10.1016/j
  17. Chen A, Seifert HS. Neisseria gonorrhoeae-mediated inhibition of apoptotic signalling in polymorphonuclear leukocytes. *Infection and Immunity*. 2011;79(11):4447–4458. DOI: 10.1128/IAI.01267-10 PMC 3257915 PMID 21844239
  18. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. *J Thromb Haemost*. 2009;8(1): 148–156
  19. Cohen S, Burns RC. *Pathways of the Pulp* (8<sup>th</sup> ed.). St. Louis: Mosby. 2002;465.

20. Cohn Lauren, Hawrylowicz Catherine, Ray Anuradha. *Biology of lymphocytes*. Middleton's Allergy: Principles and Practice (8th ed.). Philadelphia: Saunders. 2014; 203–214.  
DOI: 10.1016/B978-0-323-08593-9.00013-9  
ISBN 9780323085939  
Retrieved 22 July 2020
21. Dapper V, Emem-Chioma P, Didia B. Some hematological parameters and the Prognostic values of CD4, CD8 and total lymphocyte counts and CD4/CD8 cell count ratio in healthy HIV sero- negative, healthy HIV sero-positive and AIDS subject in Port Harcourt, Nigeria. *de Gaetano G. Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica*. 2001;86(4):349–356.
22. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. *Clinical Cancer Research*. 2004;10(15):4895–4900.  
DOI: 10.1158/1078-0432.CCR-03-0760  
PMID 15297389S2CID 9782495.
23. Demirtunc R, Duman D, Basar M, et al. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. *J Diabetes Complications*. 2009; 23:89–94.
24. Deresinski S. Infections in the diabetic patients: Strategies for the clinician. *Infect. Dis. Rep*. 1995;1:1-12.
25. Droyvold WB, Midtgjell K, Nilsen TI, Homen J. Change in body mass index and its impact on blood pressure: A prospective population study. *Int J Obes(Lond)*. 2005; 29:650-5.
26. Duprez DA, Somasundaram PE, Sigurdsson G, Hoke L, Florea N, Cohn JN. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. *Journal of Human Hypertension*. 2005;19:515–519.
27. El Haouari M, Rosado JA. Platelet function in hypertension. *Blood Cells Mol Dis*. 2009; 42:38-43.
28. Ear T, McDonald PP. Cytokine generation, promoter activation, and oxidant-independent NF $\kappa$ B activation in a transfectable human neutrophilic cellular model. *BMC Immunology*. 2008;9: 14.  
DOI: 10.1186/1471-2172-9-14  
PMC 2322942. PMID 18405381
29. Edwards SW. *Biochemistry and physiology of the neutrophil*. Cambridge University Press. 1994;6.  
ISBN 978-0-521-41698-6
30. Ermer D, Niemiec MJ, Röhm M, Glenthøj A, Borregaard N, Urban CF. *Candida albicans escapes from mouse neutrophils. Journal of Leukocyte Biology*. 2013;94(2): 223–236.  
DOI: 10.1189/jlb.0213063  
PMID 23650619  
S2CID 25619835
31. Euzizo CI, Chinko BC, Dapper DV. Comparative assessment of some white blood cell and platelet parameters amongst normotensive and hypertensive subjects in Port Harcourt, Nigeria. *Nigeria Medical Journal*. 2017;58(4):131137.  
DOI:10.4103/nmj.NMJ\_25\_17  
PMID:31057205  
PMCID: PMC6496979
32. Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. *Diabetic Vascular Disease Res*. 2010;7:251–9.
33. Davy KP, Hall JE. Obesity and hypertension: Two epidemics or one? *Am Journal Physiological Regulation Integrated Comp Physiology*. 2004;286: R803–813.  
DOI: 10.1152
34. Ferrannini E, Cushman WC. Diabetes and hypertension: The bad companions. *Lancet*. 2012;380:601–610.  
DOI: 10.1016/S0140-6736(12)60987-8
35. Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. *Diabetic Vascular Disease Resistance*. 2010;7:251–9.
36. Franco CB, Chen CC, Drukker M, Weissman IL, Galli SJ. Distinguishing mast cell and granulocyte differentiation at the single-cell level. *Cell Stem Cell*. 2010;6(4): 361–8.  
DOI: 10.1016/j.stem.2010.02.013  
PMC 2852254  
PMID 20362540
37. Garner C, Tatu T, Reittie JE, Littlewood T, Darley J, Cervino S. Genetic influences on F cells and other hematologic variables: A twin heritability study. *Blood* 2000;95(1): 342–6.
38. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. *Journal Clinical Investigation*. 2005;115:3378-84.
39. Giles TD, Materson BJ, Cohn JN, Kostis JB. Definition and classification of



- hypertension: An update *Journal Clinical Hypertension* (Greenwich). 2009;11(11): 611-4.  
DOI: 10.1111/j.1751-7176.2009.00179.x  
Erratum in: *Clinical Hypertension* (Greenwich). 2010;12(1):13.  
PMID: 19878368
40. Giovanetti TV, do Nascimento AJ, de Paula JP. Platelet indices: Laboratory and clinical applications. *Rev Bras Hematol Hemoter*. 2011;33:164–165.
  41. Gkrania-Klotsas E, Ye Z, Cooper A. J. (2010) Differential white blood cell count and type 2 diabetes: Systematic review and metaanalysis of cross-sectional and prospective studies.
  42. Glasgow RE. Compliance to diabetes regimens: conceptualization, complexity, and determinants. In *Patient Compliance in Medical Practice and Clinical Trials*. Cramer JA, Spilker B, Eds. New York, Raven Press. 1991;209–224
  43. Goto S, Hasebe T, Takagi S. Platelets: small in size but essential in the regulation of vascular homeostasis - translation from basic science to clinical medicine. 2015; 79:1871–1881.
  44. He YH, Jiang GX, Yang Y. Obesity and its associations with hypertension and type 2 diabetes among Chinese adults age 40 years and over. *Nutrition*. 2009;25:1143–9. This was a cross-sectional study of over 5000 people in the community in Shanghai showing that obesity was associated with a higher risk of both hypertension and type 2 diabetes.
  45. Hickey MJ, Kubes P. Intravascular immunity: The host-pathogen encounter in blood vessels. *Nature Reviews. Immunology*. 2009;9(5):364–375.  
DOI: 10.1038/nri2532  
PMID 19390567  
S2CID 8068543
  46. Hommels MJ, van der Ven AJ, Kroon AA, Kessels AG, van Dieijen-Visser MP, van Engelshoven JA. C-reactive protein, atherosclerosis and kidney function in hypertensive patients. *Journal of Human Hypertension*. 2005;19:521–526.
  47. International Diabetes Federation. *IDF Diabetes Atlas - 7<sup>th</sup> edition*, Brussel, Belgium. International Diabetes Federation; 2015.
  48. Tabrizi JSH, Sadeghi-Bazargani M, Farahbakhsh L, Nikniaz, Nikniaz Z. "Prevalence and associated factors of prehypertension and hypertension in Iranian population: The lifestyle promotion project (LPP); 2016.
  49. Jacobs L, Nawrot TS, de Geus B, Meeusen R, Degraeuwe B, Bernard A, et al. Subclinical responses in healthy cyclists briefly exposed to traffic-related air pollution: An intervention study. *Environmental Health*. 2010;9(64):64.  
DOI: 10.1186/1476-069X-9-64  
PMC 2984475  
PMID 20973949
  50. Jafar N, Edriss H, Nugent K. The effect of short term hyperglycemia on the innate immune System. *American Journal of Medical Sciences*. 2016;351(2)201-211.  
DOI: 10.1016/j.amjms.2015.11.0111
  51. Janeway C, Travers P, Walport M, Shlomchik M. *Immunobiology* (5th ed.). New York and London: Garland Science; 2001.  
ISBN 0-8153-4101-6
  52. Jiang H, Yan W, Li C, Wang A, Dou J, Ming M. Elevated white blood cell count is associated with higher risk of glucose metabolism disorders in middle-aged and elderly Chinese people. *International. Journal of Environmental Resource Public Health*. 2011;11:5497-5509.
  53. Joshi MB, Lad, Bharath Prasad AS, Balakrishnan A, Ramachandra L, Satamoorthy K. High glucose modulates IL-6 mediated immune homeostasis through impeding neutrophil extracellular trap formation. *FEBS Lett*. 2013;587(14): 2241-2246.
  54. Kannel WB, Brand N, Skinner JJ, Drawber TR, Mc Namara PM. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. *Ann International Medicine*. 1967;67:48-59.
  55. Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, Davidheiser S, Przybylski RJ, King GL. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. *Diabetes*. 1993;42:80–9.
  56. Kearney PM, Whelton MR, Reynolds K, Munther P, Whelton PK, He J. Global burden of hypertension: Analysis of world wide data. *Lancet*. 2005;365:217-23.
  57. Khurana. *Textbook of medical physiology* (2nd ed.). Elsevier. 2009;180.  
ISBN 978-81-8147-850-4  
Archived from the original on 2018-05-04

58. Klebanoff SJ, Clark RA. The Neutrophil: Function and clinical disorders. Elsevier/ North-Holland Amsterdam; 1978. ISBN 978-0-444-80020-6
59. Kim D, Noh JH, Lee BW, Choi YH, Chung JH, Min YK, Lee MS, Lee MK, Kim KW. The associations of total and differential white blood cell counts with obesity, hypertension, dyslipidemia and glucose intolerance in a Korean population. *J Korean Medical Science*. 2008;23:193-198.
60. Kobayashi SD, Braughton KR, Whitney AR, Voyich JM, Schwan TG, Musser JM, DeLeo FR. Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100(19):10948–10953. DOI:10.1073/pnas.1833375100 PMC 196908. PMID 12960399
61. Kobayashi SD, Malachowa N, DeLeo FR. Influence of microbes on neutrophil life and death. *Frontiers in Cellular and Infection Microbiology*. 2017;7(159)159. DOI:10.3389/fcimb.2017.00159. PMC 5410578 PMID 28507953  
Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
62. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. *Blood*. 2010;116(15):2627–34.
63. LaFleur-Brooks M. *Exploring medical language: A student-directed approach* (7th ed.). St. Louis, Missouri, US: Mosby Elsevier. 2008;398. ISBN 978-0-323-04950-4
64. Lambrecht BN, Hammad H. The immunology of asthma. *Nature Immunology*. 2015;16(1):45–56. DOI: 10.1038/ni.3049 PMID 25521684. S2CID 5451867
65. Lämmermann T, Afonso PV, Angermann BR, Wang JM, Kastenmüller W, Parent CA, Germain RN. Neutrophil swarms require LT $\beta$ 4 and integrins at sites of cell death in vivo. *Nature*. 2013;498(7454):371–375. Bibcode:2013Natur.498..371L. DOI: 10.1038/nature12175 PMC 3879961 PMID 23708969
66. Lee JM. Why young adults hold the key to assessing the obesity epidemic in children. *Arch Pediatr Adolesc Med*. 2008;162:682–687.
67. Kumar MR, Shankar R, Singh S. Hypertension among the adults in rural Varanasi: A cross-sectional study on prevalence and health seeking behavior. *Indian Journal of Preventive and Social Medicine*. 2016;47(1-2):78–83.
68. Maton D, Hopkins J, McLaughlin CW, Johnson S, Warner MQ, LaHart D, Wright JD, Kulkarni DV. *Human biology and health*. Englewood Cliffs, New Jersey, US: Prentice Hall; 1997. ISBN 0-13-981176-1
69. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. *Circ Res*. 2007;100:1261-75.
70. Mukai K, Galli SJ. "Basophils". *Basophils*. eLS. Online; 2013. DOI:10.1002/9780470015902.a0001120.p ub3. ISBN 978-0470016176  
Archived from the original on 2016-05-01
71. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. *Diabetes Care*. 2003;26:2754–2757.
72. Naredi M, Jhavar D, Krishnan D. Study of relationship between WBC count and diabetic complications. *International Journal of Advance Medicine*. 2017;4:1128-1132.
73. Nathan C. Neutrophils and immunity: Challenges and opportunities. *Nature Reviews Immunology*. 2006;6(3):173–182. DOI: 10.1038/nri1785 PMID 16498448 S2CID 1590558
74. Nworah D, Chike C, Akpa M, Nwafor A, Dapper DV. Prevalence of left ventricular hypertrophy in hypertensives and normotensives type 2 diabetic Females in Port Harcourt Nigeria *Journal of Physiological Science*. 2011;26(1):7-10.
75. Ogah OS, Okpechi I, Chukwuonye II, Akinyemi JO, Onwubere BJ, Falase AO. Blood pressure, prevalence of hypertension and hypertension related complications in Nigerian Africans: A review. *World Journal of Cardiology*. 2012;4:327–40.
76. Ohno Y, Aoki N, Nishimura A. In vitro production of interleukins-1, interleukins -6 and tumour Necrosis factor-alpha in insulin

- dependent diabetes mellitus. *J. Clin Endocrinol. Metab.* 1993;77(4):1072-1077.
77. Omman Reeba A, Kini Ameet R. Leukocyte development, kinetics, and functions. In Keohane, Elaine; 2020.
  78. Osselaer JC, Jamart J, Scheiff JM. Platelet distribution width for differential diagnosis of thrombocytosis. *Clinical Chemistry.* 1997;43(6):Part 1:1072-1076.
  79. Otto M, Catherine N, Walenga Jeanine N. Rodak's hematology: Clinical principles and applications (6<sup>th</sup> ed.). St. Louis, Missouri: Elsevier. 117–135 ISBN 978-0-323-53045-3
  80. Onwuchekwa AC, Mezie-Okoye MM, Babatunde S. Prevalence of hypertension in Kegbara-Dere, a rural community in the Niger Delta region, Nigeria. *Ethn Dis.* 2012;22:340–346
  81. Orakzai RH, Orakzai SH, Nasir K, Santos RD, Rana JS, Pimentel I, Carvalho JA, MeneghelloR, Blumenthal RS. Association of white blood cell count with systolic blood pressure within the normotensive range, *Journal of Human Hypertension.* 2006;341-347.  
DOI: 10.1038/sj.jhh.1001992  
PMID:16511508
  82. Ordinioha B. The prevalence of hypertension and its modifiable risk factors among lecturers of a medical school in Port Harcourt, South-South Nigeria: Implications for control effort. *Nigeria Journal of Clinical Practice.* 2013;16:1–4.
  83. Pantarelli C, Welch HC. Rac-GTPases and Rac-GEFs in neutrophil adhesion, migration and recruitment. *European Journal of Clinical Investigation;* 2018.
  84. Park YM, Bochner BS. Eosinophil survival and apoptosis in health and disease. *Allergy, Asthma & Immunology Research.* 2010;2(2):87–101.  
DOI: 10.4168/aaair.2010.2.2.87  
PMC 2846745  
PMID 20358022
  85. Perreault L, Pan Q, Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Mather KJ, Knowler WC. Diabetes prevention program research group. Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). *Diabetes Medical.* 2017; 34:1747–1755.  
DOI: 10.1111/dme.13453
  86. Rosales C. Neutrophil: A cell with many roles in inflammation or several cell types? *Front. Physiology.* 2018;9:113.
  87. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. *The Journal of Allergy and Clinical Immunology.* 2007;119(6):1303–10, quiz 1311–2. hdl:1885/30451  
PMID 17481712.
  88. Mendis S. Global status report on non communicable diseases. Tech. Rep., World Health Organisation; 2010.
  89. Sanderson, Colin. Interleukin-5, Eosinophils and Disease. *Blood.* 1992; 79(12):3101–3109.  
PMID 1596561.
  90. Santimone I, Di Castelnuovo A, De Curtis A. White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLI-SANI project. *Haematologica.* 2011;96:1180–1188.
  91. Schmidt MI, Duncan BB, Sharrett AR. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. *Lancet* 1999;353:1649–1652.
  92. Segal AW. How neutrophils kill microbes. *Annual Review of Immunology.* 2005; 23(5):197–223.  
DOI:10.1146/annurev.immunol.23.021704.115653  
PMC 2092448. PMID 15771570
  93. Serhan CN, Ward PA, Gilroy DW. Fundamentals of inflammation. Cambridge University Press. 2010;53–54.  
ISBN 978-0-521-88729-8
  94. Serlie MJ, Tanck MW, Sauerwein HP, Van der poll T. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. *Blood* 2008;112(10):3.  
DOI: 10.1182/blood-11-121/72 36
  95. Stegenga ME, Vander Crabben SN, Blumer RME, Levi M, Meijers JC, Silvestre-Roig C, Braster Q, Ortega-Gomez A, Soehnlein O. Neutrophils as regulators of cardiovascular inflammation. *Nat. Rev. Cardiol.* 2020;17:327-340.
  96. Simons MP, Nauseef WM, Griffith TS, Apicella MA. Neisseria gonorrhoeae delays the onset of apoptosis in polymer-phosphonuclear leukocytes. *Cellular Microbiology.* 2006;8(11):1780–1790.

- DOI: 10.1111/j.1462-5822.2006.00748.x  
PMID 16803582. S2CID 25253422.
97. Soranzo N, Spector TD, Mangino M, Kühnel B, Rendon A, Teumer A. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. *Nat Genet.* 2009;41(11):1182–90.
  98. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. *The Journal of Allergy and Clinical Immunology.* 2010;125(2 Suppl 2):S73-80. DOI:10.1016/j.jaci.2009.11.017  
PMC 2847274. PMID 20176269
  99. Surgit O, Pusuroglu H, Erturk M. Assessment of mean platelet volume in patients with resistant hypertension, controlled hypertension and normotensives. *Eurasian Journal of Medicine.* 2015;47:79–84.
  100. Tessaro FHG, Ayala TS, Nolasco EL, Bella LM, Martins JO. Insulin influences LPS-Induced TNF-alpha and IL-6 release through distinct pathway in mouse macrophages from different compartments. *Cell. Physiol. Biochem.* 2017;42(5): 2093-2104. DOI: 10.1159
  101. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. *Circulation.* 1991;84(2):613–7.
  102. Traglia M, Sala C, Masciullo C, Cverhova V, Lori F, Pistis G. Heritability and demographic analyses in the large isolated population of Val Borbera suggest advantages in mapping complex traits genes. *PLoS One.* 2009;4(10):e7554. *Turk J Haematol.* 2008;25(4):181-6. PMID:27264920
  103. Tsimihodimos V, Villalpando CG, Meigs JB, Ferrannini E. Hypertension and Diabetes Mellitus Coprediction and Time Trajectories. *Hypertension.* 2018;71:1-7.
  104. Uhm TG, Kim BS, Chung IY. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. *Allergy, Asthma & Immunology Research.* 2012; 4(2):68–79. DOI: 10.4168/aaair.2012.4.2.68  
PMC 3283796  
PMID 22379601
  105. Vagdatli E, Gounari E, Lazaridou E. Platelet distribution width: A simple, practical and specific marker of activation of coagulation. *Hippokratia.* 2010;14:28–32.
  106. Van Bom JG, Heckbert SR, Lumley T, Holmes CE, Cushman M, Folsom AR. Platelet count and the risk for thrombosis and death in the elderly. *J Thromb Hemost.* 2009;7(3):399-405
  107. Varol E, Akcay S, Icli A, Yucel H, Ozkan E, Erdogan D. Mean platelet volume in patients with prehypertension and hypertension. *Clin Hemorheol Microcirc.* 2010;45:67-72.
  108. van Zandbergen G, Gieffers J, Kothe H, Rupp J, Bollinger A, Aga E, et al. Chlamydia pneumoniae multiply in neutrophil granulocytes and delay their spontaneous apoptosis. *Journal of Immunology.* 2004;172(3):1768–1776. DOI: 10.4049/jimmunol.172.3.1768  
PMID 14734760  
S2CID 27422510
  109. Vohnout B, Gianfagna F, Lorenzet R, Cerletti C, de Gaetano G, Donati MB. Genetic regulation of inflammation-mediated activation of homeostasis: Family-based approaches in population studies. *Nutr-Metab Cardiovasc Dis.* 2010; 21(2):1001-1009.
  110. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. *Clinical Cancer Research.* 2008;14(21):6735–6741. DOI: 10.1158/1078-0432.CCR-07-4843  
PMID 18980965. S2CID 9415085
  111. Wei GS, Coady SA, Goff DC, Brancati FL, Levy D, Selvin E, Vasan RS, Fox CS. Blood pressure and the risk of developing diabetes in African Americans and whites: ARIC, CARDIA, and the Framingham Heart Study. *Diabetes Care.* 2011;34:873–879.
  112. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: Molecules, functions and pathophysiological aspects. *Laboratory Investigation; A Journal of Technical Methods and Pathology.* 2000; 80(5):617-653. DOI:10.1038/labinvest.3780067  
PMID 10830774  
S2CID 22536645
  113. World Health Organization obesity: preventing and managing the global epidemic, Report of world health organization. WHO Technical Report Series 894. Geneva Switzerland. World Health Organization; 2000.

114. World Health Organization. Global Health Status Report on Non-Communicable Diseases. Geneva, Switzerland: World Health Organization; 2010.
115. Yoo SK, Starnes TW, Deng Q, Huttenlocher A. Lyn is a redox sensor that mediates leukocyte wound attraction in vivo. *Nature*. 2011;480(7375):109–112. Bibcode:2011Natur.480..109Y. DOI:10.1038/nature10632 PMC 3228893 PMID 22101434
116. Young B, Lowe jo, Stevens A, Heath JW. *Wheater's Functional Histology* (5th ed.). Elsevier Limited; 2006. 978-0-443-06850-8
117. Olaleye MT, Adegboye OO, Akindahunsi AA. Alchornea cordifolia extracts protects Wistar albino rats against acetaminophen-induced liver damage. *African Journal of Biotechnology*. 2006;5:2439-2445.
118. Boniface PK, Ferreira SB, Kaiser CR. Recent trends in phytochemistry, ethnobotany and pharmacological significance of Alchornea cordifolia (Schumach. & Thonn.) Muell. Arg. *Journal of Ethnopharmacology*. 2016;191:216–244.
119. Adeyemi IA, Omonigbehin AE, Stella S, Oluwatosin O, Jumoke S. Antibacterial activity of extracts of Alchornea cordifolia (Schum and Thonn) Mull.Arg., Boerhavia diffusa (L) and Bridellia micranthal (Hoscht) Baill. Used in traditional medicine in Nigeria on Helicobacter pylori and four diarrhoeagenic bacterial pathoge. *African Journal of Biotechnology*. 2008;7(20):3764–3767
120. Collier HOJ, Dinneen LC, Johnson CA, Schneider C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. *Brit. J. Pharmacol*. 1968;32:295-310.
121. Kabesh1 P. Senthilkumar, Ragunathan R, R Raj Kumar. Phytochemical Analysis of Catharanthus roseus Plant Extract and its Antimicrobial Activity. *Int. J. Pure App. Biosci*. 2015;3(2):162-172.
122. Kokate A. *Phytochemical Methods*. Phytotherapy, 2<sup>nd</sup> edition. 1999;78:126-129.
123. Van Buren JP, Robinson WB. Formation of complexes between protein and tannic acid. *J. Agric. Food Chem*. 1969;1:772-777.
124. Das P, Mukherjee S, Sen R. Antiadhesive action of a marine microbial surfactant. *Colloids Surf. B Biointerfaces*. 2009a;71:183–186. DOI: 10.1016/j.colsurfb.2009.02.004
125. Leishman W. Note on a simple and rapid method of producing Romanowsky staining in malarial and other blood films. *British Medical Journal*. 1901;2:757–758.
126. Shivaji PG. Acetic acid induced painful endogenous infliction in writhing test on mice. *Journal of Pharmacology and Pharmacotherapy*. 2012;3(4):348.
127. Nsonde NGF, Kimpouni V, Dianzitoukoulou, Matsima LD, Abena AA. Evaluation of Antipyretic and Analgesic Effects of Alchornea cordifolia Schum. & Thonn. (Euphorbiaceae) and Quassia africana Baill (Simaroubaceae). *International Journal of Science*. 2020;9(1):1-7.

© 2022 Oghenechuko et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<https://www.sdiarticle5.com/review-history/82721>